Literature DB >> 30553987

Clinical tests to determine femoral version category in people with chronic hip joint pain and asymptomatic controls.

Alexandria Uding1, Nancy J Bloom2, Paul K Commean3, Travis J Hillen4, Jacqueline D Patterson5, John C Clohisy6, Marcie Harris-Hayes7.   

Abstract

STUDY
DESIGN: Controlled laboratory cross-sectional.
OBJECTIVES: To investigate the relationship between femoral version (FV), measured by MRI (FVMRI), Craig's test and hip rotation range of motion (ROM). To determine rotation ROM values associated with FVMRI categories: excessive anteversion, normal version and retroversion.
BACKGROUND: Abnormal FV values are associated with hip disorders, such as osteoarthritis, structural instability, acetabular labral tears and femoroacetabular impingement. Clinical assessment of FV may allow clinician to identify the effect of bony abnormalities on hip rotation ROM to guide clinical decisions.
METHODS: Thirty-eight participants with chronic hip joint pain (CHJP) and 38 matched controls participated. MRI was used to determine FVMRI. A digital inclinometer was used to assess Craig's test, hip internal rotation (IR) and external rotation (ER) with hip flexed to 90° (90°), and hip IR/ER with hip in neutral flexion/extension (0°). ROM differences (ROMdif) were determined by subtracting ER from IR. Pearson correlation coefficients were used to assess the relationship between FVMRI and clinical variables. One-way analysis of variance (ANOVA) was used to compare rotation ROM among FVMRI categories.
RESULTS: There were no differences between CHJP and control groups in demographics, FVMRI, Craig's test or ROM. ROMdif0° showed the highest correlation (r = 0.63) with FVMRI, then IR90° (r = 0.61) and Craig's test (r = 0.61). Differences were noted among FVMRI categories for rotation ROM except hip ER90°.
CONCLUSION: Hip rotation ROM and Craig's test may be used for screening when imaging is not indicated. A 20° difference between hip IR and ER ROM would be suggestive of abnormal FV.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Classification; Craig's test; Femoral version; Movement system; Range of motion

Mesh:

Year:  2018        PMID: 30553987      PMCID: PMC6353568          DOI: 10.1016/j.msksp.2018.12.003

Source DB:  PubMed          Journal:  Musculoskelet Sci Pract        ISSN: 2468-7812            Impact factor:   2.520


  33 in total

1.  Assessment of femoral anteversion in children with cerebral palsy: accuracy of the trochanteric prominence angle test.

Authors:  Jon R Davids; Paul Benfanti; Dawn W Blackhurst; Benjamin L Allen
Journal:  J Pediatr Orthop       Date:  2002 Mar-Apr       Impact factor: 2.324

2.  Femoral anteversion in the hip: comparison of measurement by computed tomography, magnetic resonance imaging, and physical examination.

Authors:  Itamar B Botser; George C Ozoude; Dorea E Martin; Aheed J Siddiqi; Sivaraja Kuppuswami; Benjamin G Domb
Journal:  Arthroscopy       Date:  2012-02-01       Impact factor: 4.772

3.  Concurrent criterion-related validity and reliability of a clinical test to measure femoral anteversion.

Authors:  Richard B Souza; Christopher M Powers
Journal:  J Orthop Sports Phys Ther       Date:  2009-08       Impact factor: 4.751

4.  Clinical presentation and disease characteristics of femoroacetabular impingement are sex-dependent.

Authors:  Jeffrey J Nepple; Cassandra N Riggs; James R Ross; John C Clohisy
Journal:  J Bone Joint Surg Am       Date:  2014-10-15       Impact factor: 5.284

5.  Torsion of the femur. A follow-up study in normal and abnormal conditions.

Authors:  G Fabry; G D MacEwen; A R Shands
Journal:  J Bone Joint Surg Am       Date:  1973-12       Impact factor: 5.284

6.  Femoroacetabular impingement and the cam-effect. A MRI-based quantitative anatomical study of the femoral head-neck offset.

Authors:  K Ito; M A Minka; M Leunig; S Werlen; R Ganz
Journal:  J Bone Joint Surg Br       Date:  2001-03

7.  Diminished femoral antetorsion syndrome: a cause of pain and osteoarthritis.

Authors:  D Tönnis; A Heinecke
Journal:  J Pediatr Orthop       Date:  1991 Jul-Aug       Impact factor: 2.324

8.  Hip disability and osteoarthritis outcome score. An extension of the Western Ontario and McMaster Universities Osteoarthritis Index.

Authors:  Maria Klässbo; Eva Larsson; Eva Mannevik
Journal:  Scand J Rheumatol       Date:  2003       Impact factor: 3.641

9.  Do physical examination and CT-scan measures of femoral neck anteversion and tibial torsion relate to each other?

Authors:  Morgan Sangeux; Jessica Mahy; H Kerr Graham
Journal:  Gait Posture       Date:  2013-06-18       Impact factor: 2.840

10.  Hip disability and osteoarthritis outcome score (HOOS)--validity and responsiveness in total hip replacement.

Authors:  Anna K Nilsdotter; L Stefan Lohmander; Maria Klässbo; Ewa M Roos
Journal:  BMC Musculoskelet Disord       Date:  2003-05-30       Impact factor: 2.362

View more
  4 in total

1.  Measurement of operative femoral anteversion during cementless total hip arthroplasty and influencing factors for using neck-adjustable femoral stem.

Authors:  Jingyang Sun; Bohan Zhang; Lei Geng; Qingyuan Zheng; Juncheng Li; Wenzhe Cao; Ming Ni; Guoqiang Zhang
Journal:  J Orthop Surg Res       Date:  2021-05-31       Impact factor: 2.359

Review 2.  Femoral anteversion: significance and measurement.

Authors:  Matteo Scorcelletti; Neil D Reeves; Jörn Rittweger; Alex Ireland
Journal:  J Anat       Date:  2020-06-24       Impact factor: 2.610

3.  No Association Between Intrauterine Contraceptive Devices and Musculoskeletal Hip Joint Pain.

Authors:  Nathan H Varady; Paul Abraham; Michael P Kucharik; Christopher T Eberlin; David Freccero; Eric L Smith; Scott D Martin
Journal:  Arthrosc Sports Med Rehabil       Date:  2021-08-20

Review 4.  Abnormal Femoral Anteversion Is Associated With the Development of Hip Osteoarthritis: A Systematic Review and Meta-Analysis.

Authors:  Emily A Parker; Alex M Meyer; Momin Nasir; Michael C Willey; Timothy S Brown; Robert W Westermann
Journal:  Arthrosc Sports Med Rehabil       Date:  2021-09-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.